Seeking research, innovation & technology to address the spread of COVID-19 (Closed: 7th June 2021)

Our team will then proactively disseminate the submissions and disclosures to our global network of R&D professionals in industry (which includes 95% of the top 100 biotech and pharma firms). By doing this, we’re are aiming to help mobilise the university-industry community and to provide a clear pathway for the commercialisation of ongoing COVID-19 related research, initiating meaningful conversations and partnerships that lead to collaborative development, licensing and deployment of new pandemic interventions.

What research are we looking for?

The research or technology can be anything directly or indirectly addressing the spread of SARS-CoV-2 and treatment of COVID-19. This includes diagnostics, therapeutics, vaccines, drug delivery and infection prevention. We’re also really interested to receive submissions from researchers studying long covid, next-generation vaccines and therapeutics, ways to measure and predict long-term immunity, as well as the impacts on society, psychology and the environment, and preparing for the next pandemic.

A full breakdown of the research topics we’re looking to address with the call can be found in the call document and submission form.

Who can respond to the call?

We want to hear from any researchers as well as university tech transfer and research commercialisation professionals that can provide non-confidential details of work at their institute.

This open call is not limited to institutes that already have a subscription to IN-PART. We encourage anyone in a university or research institute who is working on a project related to COVID-19 to submit a summary of their work without the need to set up a subscription. 

There are no costs or finders fees associated with submitting research or starting conversations with industry about any projects through IN-PART.

How to submit your research, expertise or technologies

If your university or institute is subscribed to IN-PART, you can submit information directly through your dashboard:

For teams or researchers not currently using IN-PART, please provide an outline of your project or technology using the submission form hosted through the link below and send it to our team by email: submissions@in-part.co.uk

Further details about the submission process can be found in the submission form, but if you have any questions please send them to submissions@in-part.co.uk and our team will get back to you promptly.

After making a submission, a member of our team will get in touch to confirm receipt and posting of the submission on our matchmaking platform, and they will then reach out with any interest from industry and to arrange an introduction via email.

Important details about the call:

If you know about any teams or academics in other universities or institutes working on COVID-19, please forward on this blog and ask them to get in touch.

• • • We offer the support of our team to disseminate COVID-19 research to relevant individuals across our industry network.
    • This does not require a subscription to our platform.
    • Any information sent to us should be non-confidential.
    • A maximum of 10 submissions can be made per person
    • If you are not already subscribed to IN-PART, please use the submission form to outline details of your project.

The call is being run in partnership with PraxisAuril, a professional association for knowledge exchange professionals, to help extend the network of universities and institutes we can reach with it.

How does this follow on from our previous open call?

With our current call, along with providing a clear pathway for the commercialisation and deployment of COVID-19 interventions, we’re looking to create an open-source of active COVID-19 research that can be accessed by industry R&D teams, and to provide a level playing field for global universities, researchers and companies to collaborate regardless of size or location. We’re looking for submissions that reflect the continuing advancement of the academic response to the pandemic, as well as new approaches to addressing the impacts and previously unforeseen aspects of this global challenge.

In March last year, we launched our first open call for COVID-19 research as universities and industries pivoted their focus to address the global pandemic. We received 174 submissions from 61 universities and research institutes across the world.

Previous submissions covered everything from responsive antiviral biomaterials (University of Toronto), serological assays (University of Hong Kong) and early warning systems for post-intensive care deterioration (University of Oxford), to point-of-care diagnostics (Cornell University), therapeutic agents (University of Sao Paulo) and first-in-class RNA vaccines (Max Planck Society).

Over 60 conversations are now underway between teams in academia and industry to further develop and deploy the solutions submitted to the call. These are being hosted by the likes of Merck, Roche, AbbVie, Ford, Philips, Thermo Fisher and GSK Vaccines, along with many others

Written by Ruth Kirk. Edited by Alex Stockham.

Copyrights reserved unless otherwise agreed – IN-PART Publishing Ltd., 2021: ‘Open call for research: Seeking research, innovation & technology to address the spread of COVID-19’

About IN-PART:

We believe brilliant connections can solve real-world problems. We match research pioneers from academia with decision-makers in industry sectors striving for a greater positive impact.

Our goal is to enable connections from around the world to match academic research with industry on a level playing field. Through our intelligent, matchmaking platform we showcase leading university innovations and connect academics with an international community of decision-makers in industry, creating meaningful dialogue and partnership.

IN-PART, a digital partnering platform for university-industry collaboration.

250+ universities and research institutes around the world currently showcase their research and innovation on IN-PART to find new collaboration partners in industry. R&D teams get free access to the platform (create an account here). There are no hidden costs and we don’t claim downstream success fees.

Discover, a bespoke scouting service for open innovation.

Through Discover, corporate R&D teams can leverage our extended academic network, which reaches multiple teams across 1,200+ universities and research institutes worldwide. In response to a specific research requirement or challenge, Discover enables R&D teams to identify new opportunities for commercialisation or to solicit proposals for new research.

Interested in speaking with our Discover team? Request a demo |  TTO or academic? Sign-up for weekly Discover emails.

Image credit: Steven Cornfield / Unsplash Licence